Jessica T Thueringer1, Natalie K Doll2, Elie Gertner3. 1. Section of Rheumatology, Regions Hospital, 640 Jackson St, Mailstop 11107E, St. Paul, MN 55101; Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN. Electronic address: Tier0073@umn.edu. 2. Department of Internal Medicine, Regions Hospital, St. Paul, MN; Department of Internal Medicine, University of Minnesota Medical School, Minneapolis, MN. 3. Section of Rheumatology, Regions Hospital, 640 Jackson St, Mailstop 11107E, St. Paul, MN 55101; Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN.
Abstract
OBJECTIVES: To report on the efficacy and safety of anakinra for treatment of acute gouty arthritis in medically complex, critically ill patients. METHODS: Retrospective chart review of 13 critically ill hospitalized patients treated with anakinra for 20 episodes of acute gouty arthritis between 2009 and 2014 at a single health plan and institution (HealthPartners Medical Group and Regions Hospital) in Saint Paul, Minnesota. Data was obtained on baseline characteristics, medical comorbidities, reason for hospitalization, prior gout treatment, reason for choosing anakinra over standard therapy, anakinra dosing, response to treatment, and adverse outcomes. RESULTS: A total of 10 patients were in the Intensive Care Unit, 1 was in the Burn Unit for extensive 3rd degree burns, 1 was critically ill with a new diagnosis of hemophagocytic lymphohistiocytosis, and 1 was critically ill in isolation with active disseminated multidrug-resistant tuberculosis. Of these patients, 85% had active infections and 92% had renal insufficiency. All patients had a significant response to anakinra treatment: 50% (10/20 episodes) within 24h, an additional 40% (8/20 episodes) by 48h, and the remaining 10% (2/20 episodes) by 72h. Anakinra was well tolerated with only 1 case of leukopenia and 1 possible infectious complication. CONCLUSIONS: Anakinra is a safe and efficacious treatment for acute gouty arthritis in medically complex, critically ill patients when standard treatment modalities cannot be used.
OBJECTIVES: To report on the efficacy and safety of anakinra for treatment of acute gouty arthritis in medically complex, critically illpatients. METHODS: Retrospective chart review of 13 critically ill hospitalized patients treated with anakinra for 20 episodes of acute gouty arthritis between 2009 and 2014 at a single health plan and institution (HealthPartners Medical Group and Regions Hospital) in Saint Paul, Minnesota. Data was obtained on baseline characteristics, medical comorbidities, reason for hospitalization, prior gout treatment, reason for choosing anakinra over standard therapy, anakinra dosing, response to treatment, and adverse outcomes. RESULTS: A total of 10 patients were in the Intensive Care Unit, 1 was in the Burn Unit for extensive 3rd degree burns, 1 was critically ill with a new diagnosis of hemophagocytic lymphohistiocytosis, and 1 was critically ill in isolation with active disseminated multidrug-resistant tuberculosis. Of these patients, 85% had active infections and 92% had renal insufficiency. All patients had a significant response to anakinra treatment: 50% (10/20 episodes) within 24h, an additional 40% (8/20 episodes) by 48h, and the remaining 10% (2/20 episodes) by 72h. Anakinra was well tolerated with only 1 case of leukopenia and 1 possible infectious complication. CONCLUSIONS: Anakinra is a safe and efficacious treatment for acute gouty arthritis in medically complex, critically illpatients when standard treatment modalities cannot be used.
Authors: U Kiltz; R Alten; M Fleck; K Krüger; B Manger; U Müller-Ladner; H Nüßlein; M Reuss-Borst; A Schwarting; H Schulze-Koops; A Tausche; J Braun Journal: Z Rheumatol Date: 2016-08 Impact factor: 1.372
Authors: Antonio Vitale; Antonella Insalaco; Paolo Sfriso; Giuseppe Lopalco; Giacomo Emmi; Marco Cattalini; Raffaele Manna; Rolando Cimaz; Roberta Priori; Rosaria Talarico; Stefano Gentileschi; Ginevra de Marchi; Micol Frassi; Romina Gallizzi; Alessandra Soriano; Maria Alessio; Daniele Cammelli; Maria C Maggio; Renzo Marcolongo; Francesco La Torre; Claudia Fabiani; Serena Colafrancesco; Francesca Ricci; Paola Galozzi; Ombretta Viapiana; Elena Verrecchia; Manuela Pardeo; Lucia Cerrito; Elena Cavallaro; Alma N Olivieri; Giuseppe Paolazzi; Gianfranco Vitiello; Armin Maier; Elena Silvestri; Chiara Stagnaro; Guido Valesini; Marta Mosca; Salvatore de Vita; Angela Tincani; Giovanni Lapadula; Bruno Frediani; Fabrizio De Benedetti; Florenzo Iannone; Leonardo Punzi; Carlo Salvarani; Mauro Galeazzi; Donato Rigante; Luca Cantarini Journal: Front Pharmacol Date: 2016-10-24 Impact factor: 5.810
Authors: Gowrie Balasubramaniam; Trisha Parker; David Turner; Mike Parker; Jonathan Scales; Patrick Harnett; Michael Harrison; Khalid Ahmed; Sweta Bhagat; Thiraupathy Marianayagam; Costantino Pitzalis; Christian Mallen; Edward Roddy; Mike Almond; Bhaskar Dasgupta Journal: BMJ Open Date: 2017-09-05 Impact factor: 2.692